How has Allogene Therapeutics's commercial paper outstanding changed year-over-year?

Allogene Therapeutics's commercial paper outstanding decreased by 0.0% year-over-year, from $6M to $6M.

What is the long-term trend for Allogene Therapeutics's commercial paper outstanding?

Over 5 years (2020 to 2025), Allogene Therapeutics's commercial paper outstanding has grown at a 6.9% compound annual growth rate (CAGR), from $4.3M to $6M.

Allogene Therapeutics ALLO Commercial Paper Outstanding

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LettersOfCreditOutstandingAmount.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's commercial paper outstanding.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's commercial paper outstanding?: Allogene Therapeutics (ALLO) reported commercial paper outstanding of $6M in Q1 2026.
How has Allogene Therapeutics's commercial paper outstanding changed year-over-year?: Allogene Therapeutics's commercial paper outstanding decreased by 0.0% year-over-year, from $6M to $6M.
What is the long-term trend for Allogene Therapeutics's commercial paper outstanding?: Over 5 years (2020 to 2025), Allogene Therapeutics's commercial paper outstanding has grown at a 6.9% compound annual growth rate (CAGR), from $4.3M to $6M.